"Armed with new knowledge about how neurodegenerative diseases alter brain structures increasing numbers of neurologists psychiatrists and other clinicians are adopting quantitative brain imaging as a tool to measure and help manage cognitive declines in patients. These imaging findings can help spur beneficial lifestyle changes in patients to reduce risk for Alzheimers disease. The concept that cognitive decline can be identified early and prevented by applying quantitative brain imaging techniques is the focus of Hot Topics in Research Preventive Neuroradiology in Brain Aging and Cognitive Decline a review published online in American Journal of Neuroradiology AJNR. Author Cyrus Raji M.D. Ph.D. of UCLA and an international team suggest a framework in which neuroradiologists work as part of a team of clinical neuroscientists neurologists psychiatrists neuropsychologists etc. to apply quantitative neuroradiology towards prevention of cognitive decline in populations at high risk for dementia  namely those with lifestyle genetic and other associated risk factors.  I believe neuroradiology and especially quantitative MRI technology will have a huge impact in the future of diagnosis and treatment of Alzheimers disease since there is compelling evidence for the baseline size of hippocampus as a key determinant of risk for future cognitive decline and since many lifestyle factors can cause atrophy or expansion in the volume of this critical brain structure says neurologist Majid Fotuhi M.D. Ph.D. of Johns Hopkins University.  Such work is already happening at UCLA and other institutions that meld these approaches into novel ways to improve patient care. We are working closely with neuroradiologists to redefine how we can reduce risk for Alzheimers with quantitative neuroimaging that helps us pinpoint symptomrelevant volume loss in the brain and subsequent targets for tracking our lifestylebased interventions says Dr. David Merrill a geriatric psychiatrist at UCLA Medical Center. Recent advances have improved the ability to characterize imaging markers along the trajectory of Alzheimers disease starting in the preclinical phase. These markers including structural functional and molecular imaging are being used in the AD diagnositc criteria AANIA  says Howard Aizenstein M.D. Ph.D. a psychiatrist at University of Pittsburgh.  Fotuhi sees imaging findings as a unique motivator for patients to make positive lifestyle changes. Patients seem to enjoy reviewing results of their imaging studies more so than reading the results of their blood tests or other clinical evaluations. For example they can see with their own eyes whether there are any strokes or atrophy in their brain. This can have a powerful impact on them and on their determination to make changes in their lifestyle in order to improve their brain health he adds. Among the lifestyle and risk factors that can be altered to potentially prevent cognitive declines are obesity diet sleep hypertension diabetes depression supplementation smoking and physical activity. It is estimated that as many as  million cases of Alzheimers dementia worldwide can be prevented with as little as a  reduction in the burden of preventable lifestyle.   The article is available online at http A related blog post is at http The American Journal of Neuroradiology AJNR is published monthly by the American Society of Neuroradiology ASNR a professional association of more than  members who specialize in diagnostic radiology of the central nervous system brain head and neck through the use of Xray MRI CT and angiography. The ASNR was founded in  and is headquartered in Oak Brook Illinois. American Journal of Neuroradiology  Enterprise Dr. Suite  Oak Brook IL  REFERENCES  Sperling RA Aisen PS Beckett LA et al. Toward defining the preclinical stages of Alzheimers disease Recommendations from the National Institute on AgingAlzheimers Association workgroups on diagnostic guidelines for Alzheimers disease. Alzheimers  dementia The Journal of the Alzheimers Association. . doi.j.jalz....  Barnes DE Yaffe K  The projected effect of risk factor reduction on Alzheimers disease prevalence. Lancet Neurol  ."